I can’t find anything pointing to diamine oxidase degrading or affecting cytosolic phospholipase A2 (cPLA2).
Cytosolic phospholipase A2 (cPLA2) is an enzyme that plays a role in the release of arachidonic acid from phospholipids, which can lead to the production of inflammatory mediators, including histamines.
Upon activation, cPLA2 releases arachidonic acid from membrane phospholipids. Arachidonic acid is then converted into eicosanoids, which can enhance the effects of histamine and promote inflammation.
Diamine oxidase (DAO) is an enzyme that helps break down histamine.
The article is about the antihistamine Fexofenadine (Allegra) blocking cPLA2 effectively by reducing inflammation (by blocking histamine receptors) and preventing cartilage cells from aging.
My joint pain and inflammation was gone immediately when I began taking diamine oxidase enzyme. Why take a selective peripheral H₁ blocker when you can decrease histamines with diamine oxidase enzyme in the entire body and have no need for the histamine blocker?
Fexofenadine is a selective peripheral H₁ blocker. It is classified as a second-generation antihistamine because it is less able to pass the blood–brain barrier and cause sedation, compared to first-generation antihistamines like diphenhydramine (Benadryl).
Why block the histamines released by Cytosolic phospholipase A2 (cPLA2) through arachidonic acid in a selective area rather than degrade them in the entire body?